Billiontoone (NASDAQ:BLLN) Price Target Cut to $140.00 by Analysts at BTIG Research

Billiontoone (NASDAQ:BLLN) had its price target trimmed by BTIG Research from $160.00 to $140.00 in a research report sent to investors on Thursday, MarketBeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on BLLN. Wells Fargo & Company assumed coverage on Billiontoone in a research note on Monday, December 1st. They issued an “equal weight” rating and a $110.00 price objective for the company. William Blair assumed coverage on shares of Billiontoone in a research note on Monday, December 1st. They set an “outperform” rating on the stock. Guggenheim initiated coverage on shares of Billiontoone in a research report on Tuesday, January 6th. They set a “buy” rating and a $120.00 price target on the stock. Piper Sandler reissued an “overweight” rating on shares of Billiontoone in a research note on Wednesday, December 10th. Finally, JPMorgan Chase & Co. cut their target price on shares of Billiontoone from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $129.57.

Billiontoone Stock Down 10.7%

Billiontoone stock opened at $72.17 on Thursday. The company has a 50 day moving average of $85.87. Billiontoone has a 1 year low of $66.00 and a 1 year high of $138.70. The stock has a market cap of $3.30 billion and a P/E ratio of 721.70.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.07. The company had revenue of $96.05 million during the quarter, compared to analyst estimates of $85.85 million. The company’s revenue was up 113.0% on a year-over-year basis.

Institutional Investors Weigh In On Billiontoone

A number of large investors have recently modified their holdings of BLLN. Adams Street Partners LLC acquired a new stake in shares of Billiontoone in the 4th quarter valued at $140,063,000. Baillie Gifford & Co. purchased a new position in Billiontoone in the fourth quarter valued at $103,786,000. Price T Rowe Associates Inc. MD acquired a new stake in Billiontoone in the fourth quarter valued at $39,717,000. JPMorgan Chase & Co. purchased a new stake in Billiontoone during the 4th quarter worth about $32,078,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Billiontoone during the 4th quarter worth about $18,631,000.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 results beat and company raised 2026 revenue guidance — BillionToOne reported $0.11 EPS (vs. $0.04 consensus) and $96.05M revenue (vs. $85.85M est.), with revenue up 113% year/year; management raised FY‑2026 revenue guidance to $430M–$445M (well above street consensus). This is the core bullish fundamental catalyst. GlobeNewswire: Earnings & Guidance
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating with a $120 price target — a supportive analyst vote that implies meaningful upside from current levels. Benzinga: Guggenheim Rating
• Neutral Sentiment: BTIG cut its price target from $160 to $140 but kept a “buy” rating — still constructive long-term, though the lower PT trims upside expectations. StreetInsider: BTIG PT Lowered
• Neutral Sentiment: Reported short interest entries show zero/NaN values and a 0.0 days ratio — the data appears unreliable and is unlikely to explain today’s move. (No meaningful short-interest signal.)
• Negative Sentiment: Wells Fargo lowered its price target from $110 to $90 and set an “equal weight” rating — a clear downdraft to near‑term sentiment and one of the more immediate bearish analyst actions. Benzinga: Wells Fargo PT Cut

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.